Tobacco stock Altria Group, Inc. (NYSE: MO ) has had an underwhelming 2025 so far at the stock markets compared with its peers. Even with its ~11% increase YTD, which is considerably ahead of the consumer staples sector, as seen from the 3.2% rise inManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her ...

Core Insights - Altria has transitioned into a primarily tobacco-focused company, while Philip Morris International has a more diversified and stronger business model [1][4] Market Share and Brand Performance - Altria's flagship brand, Marlboro, holds a 41% market share in North America, contributing to an overall market share of approximately 45% when including smaller brands [3] - Marlboro has recently lost market share, indicating a decline in Altria's competitive position [5] Business Operations and Challenges - Altria's cigarette volume fell by 13.7% in Q1 2025, continuing a long-term downward trend, which is impacting its business significantly [5][6] - The company has faced substantial financial missteps, resulting in billions of dollars in write-downs, highlighting its struggles in adapting to market changes [6] Comparison with Philip Morris - Philip Morris has shown resilience, with cigarette volumes increasing in foreign markets during the same period, leading to a 0.4-percentage-point market share gain [7] - Philip Morris's non-cigarette operations are thriving, generating 42% of its revenue and 44% of its profits in Q1 2025, with strong performance in vapes and pouches [8] Investment Considerations - Investors in Altria are betting on the company's ability to pivot towards non-cigarette businesses, while Philip Morris is currently seen as the stronger investment option due to its successful execution and market performance [9]

Core Insights - The FDA has authorized the sale of Juul's e-cigarette device and refill cartridges in tobacco and menthol flavors, marking a significant regulatory approval after years of scrutiny [1][3][4] - This decision provides a potential recovery path for Juul, which faced bankruptcy risks following a federal ban in 2022 [1][2] - The approval is seen as part of a broader expectation that regulatory hurdles for new vaping products may be eased under the current administration [4] Regulatory Context - The FDA's 2022 ban on Juul's products was temporarily stayed after the company appealed the decision [2][8] - The FDA's rigorous evaluation of Juul's data led to the conclusion that marketing approval was appropriate for public health protection [3] - The agency has faced criticism for slow product authorizations and the proliferation of unauthorized products in the market [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Group 1 - Altria is part of the Consumer Staples sector, which includes 178 individual stocks and has a Zacks Sector Rank of 14, indicating its relative strength among sectors [2] - Altria currently holds a Zacks Rank of 2 (Buy), with a 0.9% increase in the Zacks Consensus Estimate for its full-year earnings over the past 90 days, reflecting improving analyst sentiment [3] - Year-to-date, Altria has returned 10.5%, outperforming the average gain of 5% for Consumer Staples stocks [4] Group 2 - Altria belongs to the Tobacco industry, which consists of 7 individual stocks and is ranked 65 in the Zacks Industry Rank, with an average year-to-date gain of 39.3%, indicating that Altria is slightly underperforming its industry [5] - In comparison, Carlsberg AS, another stock in the Consumer Staples sector, has achieved a year-to-date return of 48.8% and has a Zacks Rank of 2 (Buy) [4][5] - The Beverages - Alcohol industry, where Carlsberg AS is categorized, has 15 stocks and is ranked 146, with a year-to-date increase of 2.1% [6]

Core Viewpoint - Constellation Brands and Altria are both considered stable blue chip stocks, but Altria has outperformed Constellation significantly over the past three years, raising questions about future investment potential [1][2]. Constellation Brands - Constellation Brands generates most of its revenue from its beer business, with popular brands like Modelo and Corona, and a smaller portion from wine and spirits [4]. - The company faces three major challenges: declining beer consumption among younger consumers, decreasing sales of lower-end wines, and increased costs due to tariffs on imported Mexican beers [5][6]. - Analysts expect Constellation's revenue to decline from $10.2 billion in 2024 to $9.9 billion in 2027, while its earnings per share (EPS) is projected to grow at a compound annual growth rate (CAGR) of 7% [8]. - Despite a low valuation at 14 times forward earnings and a forward yield of 2.5%, the lack of near-term catalysts makes it an unappealing investment [9]. Altria - Altria primarily generates revenue from its Marlboro cigarettes and has a strong domestic focus, which protects it from tariffs and foreign-exchange issues [10][11]. - The company has been countering declining smoking rates by raising cigarette prices, cutting costs, and expanding its smokeless product portfolio through investments and acquisitions [12]. - Following a setback with its investment in Juul, Altria acquired Njoy for $2.8 billion in 2023, which is expected to boost EPS starting in 2026 [13]. - Analysts predict Altria's revenue will dip slightly from $20.4 billion in 2024 to $20.2 billion in 2027, but its EPS is expected to grow at a steady CAGR of 5% from 2025 to 2027 [14][15]. - Altria's stock is considered cheap at 12 times forward earnings, with a substantial forward yield of nearly 7%, making it a more stable investment compared to Constellation [15]. Investment Recommendation - Altria is viewed as the better investment option due to its more stable business model, larger dividend, and lower valuation multiple compared to Constellation Brands [16].

Core Insights - Altria Group, Inc. has shown resilience in a challenging environment, primarily driven by its effective pricing strategy despite volume pressures in the cigarette category and strict regulations [1][2][3] Pricing Strategy and Revenue Growth - In Q1 2025, Altria's pricing actions significantly boosted revenues in both Smokeable Products and Oral Tobacco segments, offsetting volume declines and highlighting the inelastic nature of cigarette demand [2][7] - The company's ability to raise prices without losing consumers has been crucial for maintaining profitability, with management projecting adjusted EPS for 2025 to be between $5.30 and $5.45, indicating a year-over-year growth of 2% to 5% from the 2024 base of $5.19 [3][7] Comparison with Competitors - Philip Morris International reported a 10.2% organic net revenue growth and a 16% organic operating income growth in Q1 2025, with pricing contributing significantly to its revenue growth [4] - Turning Point Brands focuses on brand strength and market positioning rather than aggressive pricing, showing volume resilience through consumer trade-down trends [5] Valuation and Earnings Estimates - Altria's shares have increased by 24.4% over the past year, compared to the industry's growth of 55.6% [6] - The forward price-to-earnings ratio for Altria is 10.72X, which is below the industry average of 15.09X [9] - The Zacks Consensus Estimate for Altria's 2025 earnings suggests a year-over-year growth of 4.7%, with 2026 earnings expected to increase by 3.1% [10]

Core Insights - Altria (MO) is positioned to potentially continue its earnings-beat streak in the upcoming report, having a history of beating earnings estimates, particularly in the last two quarters with an average surprise of 3.35% [1][2] Earnings Performance - For the last reported quarter, Altria achieved earnings of $1.23 per share, surpassing the Zacks Consensus Estimate of $1.17 per share, resulting in a surprise of 5.13% [2] - In the previous quarter, Altria was expected to post earnings of $1.27 per share but delivered $1.29 per share, yielding a surprise of 1.57% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Altria, with a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of an earnings beat [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced a positive surprise nearly 70% of the time [6] Current Earnings ESP and Outlook - Altria currently has an Earnings ESP of +0.42%, suggesting analysts are optimistic about its near-term earnings potential [8] - Combined with a Zacks Rank of 2 (Buy), this indicates a strong possibility of another earnings beat in the upcoming report, expected on July 30, 2025 [8]

Core Viewpoint - Altria Group's stock is experiencing a significant decline following a negative rating from Jefferies, despite a generally positive market trend [1][3]. Group 1: Stock Performance - Altria's stock price fell by 4.1% as of 2:30 p.m. ET, with a maximum decline of 4.5% earlier in the trading session [1]. - Despite the current pullback, Altria's stock has increased approximately 24% over the past year [1]. Group 2: Analyst Coverage - Jefferies initiated coverage on Altria with an underperform rating and set a one-year price target of $50 per share, indicating a potential downside of about 12.5% [3]. - The lead analyst, Edward Mundy, believes that Altria's valuation has become stretched following its recent stock price increase [3]. Group 3: Market Trends - Altria is facing a potential secular decline in smokable tobacco products, with consistent declines in unit sales for cigarettes in recent years [4]. - The company has been able to offset some declines in cigarette unit volumes through price increases [4]. Group 4: Future Outlook - Altria is focusing on increasing demand for smoke-free products and has seen some recent successes in this area [5]. - The company's current valuation stands at approximately 10.6 times this year's expected earnings, with a dividend yield of around 7.2% [5].

Core Insights - Altria Group, Inc. (MO) has achieved a 21.2% gain over the past six months, outperforming the Zacks Consumer Staples sector's growth of 10.7% and the S&P 500's advance of 6.3% [1] - The stock is trading near its 52-week high of $60.25, just 1.6% below the peak reached on May 7, 2025, indicating strong upward momentum [4] - Altria's strong performance is attributed to robust pricing power in its core combustible tobacco segment, particularly with its flagship brand, Marlboro, which commands a 10.8% net price realization [8][9] Performance Comparison - Altria's stock performance is strong relative to major tobacco players, with Philip Morris International Inc. (PM) surging 51.2%, Turning Point Brands, Inc. (TPB) gaining 28.5%, and British American Tobacco p.l.c. (BTI) increasing by 37% over the same period [3] - The stock's position above key technical benchmarks, including the 50-day and 200-day moving averages, suggests sustained bullish momentum [4][5] Financial Metrics - Altria repurchased 5.7 million shares and paid $1.7 billion in dividends in the first quarter of 2025, reinforcing its commitment to shareholder returns [6][12] - The company's forward 12-month P/E ratio is 11.03, which is attractive compared to the industry average of 15.28, positioning Altria as a compelling value opportunity [13][15] Growth Drivers - The Marlboro brand expanded its share of the premium category to 59.3% in the first quarter, supported by advanced Revenue Growth Management tools [9] - Altria's smoke-free product line, particularly the oral nicotine pouch brand on!, saw an 18% increase in shipments, capturing 8.8% of the oral tobacco category and 17.9% of the nicotine pouch segment [10] - The company is addressing regulatory challenges in the e-vapor category and is committed to refining its product pipeline for future market re-entry [11] Investment Outlook - Altria's combination of strong pricing power, growth in smoke-free products, and a proactive approach to regulatory challenges positions it well for long-term performance [18] - The stock is viewed as a solid opportunity for value and income-focused investors, particularly given its discounted valuation and attractive dividend yield [18]